Contralateral breast radiation doses in breast cancer patients treated with helical tomotherapy

We aimed to evaluate contralateral breast doses calculated with a Treatment Planning System (TPS) and verified with metal oxide semiconductor field effect transistor (MOSFET) detectors in patients with earlystage breast cancer (BC) who received helical tomotherapy (HT) after breast-conserving surgery. The dosimetric data of 30 patients (15 left-sided and 15 right-sided) with BC treated with 50.4 Gy to the whole breast and 64.4 Gy to the tumor bed in 28 fractions were analyzed. TPS doses were calculated and MOSFET doses were measured in the contralateral breast (CB) at cranial, caudal, and midpoint and 2 cm lateral to the central point. TPS and MOSFET doses were compared in the entire cohort as well as by tumor location (inner vs outer quadrant) and planning target volume of the breast ( < 1200 cc vs >= 1200 cc). The average doses at superior, inferior, central, and lateral points calculated with the TPS were 0.26 +/- 0.15 cGy, 0.21 +/- 0.09 cGy, 0.65 +/- 0.14 cGy, and 0.50 +/- 0.11 cGy, respectively, and were 0.37 +/- 0.16 cGy, 0.34 +/- 0.12 cGy, 0.60 +/- 0.18 cGy, and 0.34 +/- 0.15 cGy, respectively in MOSFET readings. Except for the central point, TPS-calculated doses and MOSFET readings were differed. The doses to the CB in patients with inner and outer quadrant tumors were not significantly different. In patients with large breasts, MOSFET doses were higher at superior and lateral points than TPS doses, but TPS doses were greater at inferior points. MOSFET readings were higher than TPS calculated doses in patients with inner or outer quadrant tumors in small or large breast volumes. The dose calculated by the TPS and that measured by MOSFET differed by a very small amount. The maximum dose to the CB administered at the midpoint was 1.8 Gy, as calculated using the TPS and confirmed using MOSFET detectors, in patients with early-stage BC undergoing breast-only radiotherapy with HT. (c) 2022 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.